AbbVie Inc. ($ABBV) Stock Forecast: Up 6.1% Today

What is AbbVie Inc.?

AbbVie (ABBV) is a pharmaceutical company known for its focus on immunology drugs such as Humira, Skyrizi, and Rinvoq. The company has been performing well in the market, with a strong bullish movement today.

Why is AbbVie Inc. going up?

ABBV stock is up 6.1% on Jan 31, 2025 20:40

• AbbVie's strong bullish movement today is linked to its Q4 earnings and sales performance surpassing expectations and an increased sales forecast for key drugs like Skyrizi and Rinvoq.
• The market reacted positively to AbbVie's revenue growth, particularly due to the success of newer immunology drugs that offset the decline in Humira sales.
• Investor confidence in AbbVie's future appears high, evident in the company's market outperformance over the past 5 years and the raised revenue forecast for key drugs.
• AbbVie's focus on innovative drugs and robust financial performance have been key drivers of its bullish movement today, reflecting investor confidence in the company's growth trajectory.

ABBV Price Chart

ABBV Technical Analysis

ABBV News

AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs

ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.

https://www.zacks.com/stock/news/2407813/abbvie-beats-on-q4-earnings-sales-raises-sales-view-for-key-drugs

AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline - AbbVie ( NYSE:ABBV )

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi ( +57.9% ) and Rinvoq ( +47.1% ) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 billion, including $20B for Skyrizi and $11B for Rinvoq. AbbVie Inc.

https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline

AbbVie ( ABBV ) Q4 Earnings and Revenues Surpass Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.41% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2407358/abbvie-abbv-q4-earnings-and-revenues-surpass-estimates

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - AbbVie ( NYSE:ABBV )

AbbVie ABBV has outperformed the market over the past 5 years by 2.84% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $310.89 billion.

https://www.benzinga.com/insights/news/25/01/43372190/100-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? - Novartis ( NYSE:NVS )

Novartis shows strong bullish momentum, while AbbVie remains range-bound ahead of its Q4 earnings reports. Investors should watch key resistance levels - ABBV above $177 and NVS above $106 - for potential post-earnings moves. Get the Real Story Behind Every Major Earnings Report As AbbVie Inc.

https://www.benzinga.com/general/biotech/25/01/43350321/abbvie-vs-novartis-which-has-the-technical-edge-before-q4-earnings

Trending Today

Pepe ($PEPE) Crypto Forecast: Down 5.0% Today

TRON ($TRX) Crypto Forecast: Down 5.0% Today

Movement ($MOVE) Crypto Forecast: Down 7.6% Today

Ondo ($ONDO) Crypto Forecast: Down 7.9% Today

Litecoin ($LTC) Crypto Forecast: Down 6.8% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Down 5.9% Today

Dogecoin ($DOGE) Crypto Forecast: Down 6.3% Today

Bittensor ($TAO) Crypto Forecast: Down 5.5% Today

Stellar ($XLM) Crypto Forecast: Down 5.4% Today

Ethena ($ENA) Crypto Forecast: Up 10.7% Today

AbbVie Inc. Price History

30.09.2024 - ABBV Stock was up 5.8%

• AbbVie reported third-quarter earnings that exceeded expectations, with adjusted EPS of $3.00 and net revenues of $14.46 billion, driven by the strong performance of Skyrizi and Rinvoq.
• The surpassing of Q3 earnings and revenue estimates by AbbVie indicates a positive outlook for the company's future growth and profitability.
• Despite concerns reflected in bearish signals ahead of the earnings report, AbbVie's actual performance proved to be robust, leading to a bullish market movement.
• Investor focus on the sales performance of AbbVie's key drugs, Rinvoq and Skyrizi, likely contributed to the positive sentiment surrounding the stock.

30.09.2024 - ABBV Stock was up 2.6%

• AbbVie reported third-quarter earnings that exceeded expectations, with adjusted EPS of $3.00 and net revenues of $14.46 billion, driven by the strong performance of Skyrizi and Rinvoq.
• Investor focus on the sales performance of these blockbuster drugs likely contributed to the bullish movement of ABBV stock.
• The positive earnings report and outperformance of ABBV compared to the broader market led to increased investor confidence and a rise in the stock price.

22.10.2024 - ABBV Stock was up 5.3%

• ABBV experienced a significant bullish surge recently, attributed to:
• Positive outlook from top financial analysts, endorsing the stock and hinting at forthcoming growth.
• Noteworthy increase in bullish options trading, showcasing investors' optimistic stance.
• Approval of ABBV's Elahere in Europe for treating platinum-resistant ovarian cancer, widening its market scope and potentially elevating revenue.
• Despite a recent 11% stock price dip, there is a prevailing belief among investors in ABBV's capability to surmount challenges and resume strong growth, fueling heightened buying activity and the bullish upturn.

31.09.2024 - ABBV Stock was up 7.5%

• AbbVie reported strong third-quarter earnings and sales, surpassing expectations and leading to a bullish movement in the stock.
• The company's increased EPS guidance and positive sales performance for its immunology drugs contributed to investor confidence and drove the stock higher.
• Investor focus on the sales performance of Rinvoq and Skyrizi likely played a significant role in the market's positive reaction to AbbVie's earnings report.
• The bullish movement reflects market optimism regarding AbbVie's future prospects and the continued success of its key products in the pharmaceutical industry.

31.09.2024 - ABBV Stock was up 7.6%

• AbbVie reported strong third-quarter earnings and sales, exceeding expectations and raising its EPS guidance for 2024.
• The success was driven by robust sales of its popular immunology medications, Rinvoq and Skyrizi.
• Investor confidence in AbbVie grew due to the company's optimistic outlook and ability to outperform market predictions.
• The surge in AbbVie's stock price reflects market optimism towards the company's financial performance and future potential.

15.00.2025 - ABBV Stock was down 0.9%

• The stock of AbbVie has seen a significant decline in the past three months, prompting investors to evaluate whether to buy, hold, or sell their positions. This downward trend may have contributed to today's bearish movement.
• The partnership announcement with Simcere Zaiming to develop a novel trispecific antibody candidate in multiple myeloma could have initially sparked investor interest. However, the market reaction to this news seems to have been overshadowed by broader market conditions or other factors.
• Despite the positive sentiment from unusual options activity indicating a bullish approach towards AbbVie, the stock still faced a notable decline today. This discrepancy between investor sentiment and market performance suggests that external factors or broader industry trends might be influencing AbbVie's stock movement.

31.00.2025 - ABBV Stock was up 6.1%

• AbbVie's strong bullish movement today is linked to its Q4 earnings and sales performance surpassing expectations and an increased sales forecast for key drugs like Skyrizi and Rinvoq.
• The market reacted positively to AbbVie's revenue growth, particularly due to the success of newer immunology drugs that offset the decline in Humira sales.
• Investor confidence in AbbVie's future appears high, evident in the company's market outperformance over the past 5 years and the raised revenue forecast for key drugs.
• AbbVie's focus on innovative drugs and robust financial performance have been key drivers of its bullish movement today, reflecting investor confidence in the company's growth trajectory.

31.00.2025 - ABBV Stock was up 7.7%

• AbbVie surpassed Q4 earnings projections, primarily driven by robust sales of Skyrizi and Rinvoq leading to revenue growth.
• The company increased its revenue forecast for Skyrizi and Rinvoq for 2027, reflecting a high level of confidence in the performance of these medications.
• The market displayed optimism towards AbbVie's future prospects, as demonstrated by today's bullish movement in the stock.
• Emphasis on the sales figures of critical drugs like Rinvoq and Skyrizi preceding the earnings announcement likely influenced the positive market sentiment surrounding AbbVie.

31.00.2025 - ABBV Stock was up 7.5%

• AbbVie's favorable market movement today is driven by optimistic projections for its immunology division, anticipating growth rates of 7% in 2025 and 10-11% in 2026-2027.
• Shareholders are eagerly anticipating AbbVie's Q4 financial results, especially focusing on the sales performance of Rinvoq and Skyrizi, which serve as pivotal growth catalysts for the company.
• Analysts have raised AbbVie's price target to $208, instilling further confidence among investors.
• A comparison of technical indicators with Novartis reveals AbbVie's current stability leading up to its earnings announcement. However, identified resistance levels exceeding $177 could potentially trigger positive market sentiment following the report.

26.03.2024 - ABBV Stock was down 5.1%

• Strong Q1 2024 earnings were reported by AbbVie with an EPS of $2.31, surpassing analyst projections.
• Performance attributed to the ex-Humira growth platform despite revenue obstacles.
• Market reaction, though bearish, reflected concerns over revenue challenges post the positive earnings beat.
• Investor caution may arise regarding AbbVie's capability to maintain revenue growth amidst pharmaceutical industry challenges.

17.06.2024 - ABBV Stock was up 3.5%

• Recent actions by prominent figures in the finance industry, like selling Bristol Myers and increasing holdings in AbbVie, likely contributed to heightened investor confidence in ABBV.
• A focus on high-yield dividend investments as a strategy to combat inflation may have encouraged investors to consider ABBV, particularly if the company offers an attractive dividend yield.
• Given the current economic climate and the inclination towards recession-resistant assets, it is probable that the general desire for stable investments during uncertain times influenced the positive performance of ABBV.

25.06.2024 - ABBV Stock was up 5.2%

• AbbVie raised its adjusted earnings guidance for the full year, indicating positive growth prospects and financial performance.
• The hike in full-year earnings guidance was primarily driven by strong demand for one of AbbVie's key drugs, Humira, surpassing estimates.
• Despite a drop in adjusted profit for Q2, AbbVie's higher revenues and results surpassing expectations contributed to the overall positive market sentiment.
• The company's increase in annual profit forecast was fueled by robust sales of its immunology drugs, boosting investor confidence and contributing to the market's bullish movement.